Sequestering HMGB1 via DNA-conjugated beads ameliorates murine colitis

PLoS ONE

Volumn 9, Issue 8, 2014, Pages

  Ju, Zhongliang ^a   Chavan, Sangeeta S ^a   Antoine, Daniel J ^b   Dancho, Meghan ^a   Tsaava, Teá ^a   Li, Jianhua ^a   Lu, Ben ^a   Levine, Yaakov A ^c   Stiegler, Andrew ^c   Tamari, Yehuda ^c   Al Abed, Yousef ^a   Roth, Jesse ^a   Tracey, Kevin J ^a   Yang, Huan ^a  

^a FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH   (United States)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

^c SetPoint Medical Corporation ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B1 DNA CONJUGATED BEAD; B2 DNA CONJUGATED BEAD; B3 DNA CONJUGATED BEAD; B4 DNA CONJUGATED BEAD; DEXTRAN SULFATE; DNA CONJUGATED BEAD; HIGH MOBILITY GROUP B1 PROTEIN; INTERFERON; INTERLEUKIN 10; LACTATE DEHYDROGENASE; LIPOPOLYSACCHARIDE; NANOBEAD; POLYINOSINIC POLYCYTIDYLIC ACID; SEPHAROSE; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; CYTOKINE; HMGB1 PROTEIN, MOUSE; MICROSPHERE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BODY WEIGHT; CELL VIABILITY; COLITIS; COLON INJURY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DRUG ACTIVITY; DRUG BINDING; DRUG EFFECT; DRUG MECHANISM; EX VIVO STUDY; FECES ANALYSIS; FEMALE; HUMAN; HUMAN CELL; MACROPHAGE ACTIVATION; MALE; MOUSE; NONHUMAN; PROTEIN DNA BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; TISSUE INJURY; ANIMAL; ANTAGONISTS AND INHIBITORS; BLOOD; C57BL MOUSE; CACO 2 CELL LINE; CHEMISTRY; COLON; FECES; GENETICS; HELA CELL LINE; KNOCKOUT MOUSE; METABOLISM; PATHOLOGY;

ANIMALS; CACO-2 CELLS; COLITIS; COLON; CYTOKINES; FECES; HELA CELLS; HMGB1 PROTEIN; HUMANS; INTERLEUKIN-10; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICROSPHERES; SEPHAROSE;

EID: 84928079776     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0103992     Document Type: Article

References (52)

1. Garland CF, Lilienfeld AM, Mendeloff AI, Markowitz JA, Terrell KB, et al. (1981) Incidence rates of ulcerative colitis and Crohn's disease in fifteen areas of the United States. Gastroenterology 81: 1115-1124. (Pubitemid 11029694)
2. Loftus EV Jr (2004) Clinical epidemiology of inflammatory bowel disease: Incidence, prevalence, and environmental influences. Gastroenterology 126: 1504-1517.
3. Xavier RJ, Podolsky DK (2007) Unravelling the pathogenesis of inflammatory bowel disease. Nature 448: 427-434. (Pubitemid 47123518)
4. Sartor RB (2010) Genetics and environmental interactions shape the intestinal microbiome to promote inflammatory bowel disease versus mucosal homeostasis. Gastroenterology 139: 1816-1819.
5. Graff LA, Walker JR, Clara I, Lix L, Miller N, et al. (2009) Stress coping, distress, and health perceptions in inflammatory bowel disease and community controls. The American journal of gastroenterology 104: 2959-2969.
6. Graff LA, Vincent N, Walker JR, Clara I, Carr R, et al. (2011) A population-based study of fatigue and sleep difficulties in inflammatory bowel disease. Inflammatory bowel diseases 17: 1882-1889.
7. Lix LM, Graff LA, Walker JR, Clara I, Rawsthorne P, et al. (2008) Longitudinal study of quality of life and psychological functioning for active, fluctuating, and inactive disease patterns in inflammatory bowel disease. Inflammatory bowel diseases 14: 1575-1584.
8. Magro F, Portela F (2010) Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy 24 Suppl 1: 3-14.
9. Stros M (2010) HMGB proteins: interactions with DNA and chromatin. Biochimica et biophysica acta 1799: 101-113.
10. Wang H, Bloom O, Zhang M, Vishnubhakat JM, Ombrellino M, et al. (1999) HMG-1 as a late mediator of endotoxin lethality in mice. Science 285: 248-251. (Pubitemid 29329996)
11. Yang H, Ochani M, Li J, Qiang X, Tanovic M, et al. (2004) Reversing established sepsis with antagonists of endogenous high-mobility group box 1. Proceedings of the National Academy of Sciences of the United States of America 101: 296-301. (Pubitemid 38084244)
12. Yang H, Antoine DJ, Andersson U, Tracey KJ (2013) The many faces of HMGB1: molecular structure-functional activity in inflammation, apoptosis, and chemotaxis. Journal of leukocyte biology 93: 865-873.
13. Maeda S, Hikiba Y, Shibata W, Ohmae T, Yanai A, et al. (2007) Essential roles of high-mobility group box 1 in the development of murine colitis and colitis-associated cancer. Biochemical and biophysical research communications 360: 394-400. (Pubitemid 47030357)
14. Vitali R, Stronati L, Negroni A, Di Nardo G, Pierdomenico M, et al. (2011) Fecal HMGB1 is a novel marker of intestinal mucosal inflammation in pediatric inflammatory bowel disease. The American journal of gastroenterology 106: 2029-2040.
15. Sappington PL, Yang R, Yang H, Tracey KJ, Delude RL, et al. (2002) HMGB1 B box increases the permeability of Caco-2 enterocytic monolayers and impairs intestinal barrier function in mice. Gastroenterology 123: 790-802. (Pubitemid 34977085)
16. Yang R, Harada T, Mollen KP, Prince JM, Levy RM, et al. (2006) Anti-HMGB1 neutralizing antibody ameliorates gut barrier dysfunction and improves survival after hemorrhagic shock. Molecular medicine 12: 105-114. (Pubitemid 44454098)
17. Dave SH, Tilstra JS, Matsuoka K, Li F, DeMarco RA, et al. (2009) Ethyl pyruvate decreases HMGB1 release and ameliorates murine colitis. Journal of leukocyte biology 86: 633-643.
18. Vitali R, Palone F, Cucchiara S, Negroni A, Cavone L, et al. (2013) Dipotassium Glycyrrhizate Inhibits HMGB1-Dependent Inflammation and Ameliorates Colitis in Mice. PloS one 8: e66527.
19. Yang H, Lundback P, Ottosson L, Erlandsson-Harris H, Venereau E, et al. (2012) Redox modification of cysteine residues regulates the cytokine activity of high mobility group box-1 (HMGB1). Molecular medicine 18: 250-259.
20. Antoine DJ, Williams DP, Kipar A, Laverty H, Park BK (2010) Diet restriction inhibits apoptosis and HMGB1 oxidation and promotes inflammatory cell recruitment during acetaminophen hepatotoxicity. Molecular medicine 16: 479-490.
21. Antoine DJ, Jenkins RE, Dear JW, Williams DP, McGill MR, et al. (2012) Molecular forms of HMGB1 and keratin-18 as mechanistic biomarkers for mode of cell death and prognosis during clinical acetaminophen hepatotoxicity. Journal of hepatology 56: 1070-1079.
22. Antoine DJ, Harris HE, Andersson U, Tracey KJ, Bianchi ME (2014) A systematic nomenclature for the redox states of high mobility group box (HMGB) proteins. Molecular medicine 20(1): 135-137.
23. Bonaldi T, Talamo F, Scaffidi P, Ferrera D, Porto A, et al. (2003) Monocytic cells hyperacetylate chromatin protein HMGB1 to redirect it towards secretion. The EMBO journal 22: 5551-5560. (Pubitemid 37279964)
24. Lu B, Nakamura T, Inouye K, Li J, Tang Y, et al. (2012) Novel role of PKR in inflammasome activation and HMGB1 release. Nature 488: 670-674.
25. Lu B, Antoine DJ, Kwan K, Lundback P, Wahamaa H, et al. (2014) JAK/STAT1 signaling promotes HMGB1 hyperacetylation and nuclear translocation. Proceedings of the National Academy of Sciences of the United States of America 111: 3068-3073.
26. Bianchi ME, Beltrame M (1998) Flexing DNA: HMG-box proteins and their partners. American journal of human genetics 63: 1573-1577. (Pubitemid 30415718)
27. Webb M, Payet D, Lee KB, Travers AA, Thomas JO (2001) Structural requirements for cooperative binding of HMG1 to DNA minicircles. Journal of molecular biology 309: 79-88. (Pubitemid 32553509)
28. Hill DA, Reeves R (1997) Competition between HMG-I(Y), HMG-1 and histone H1 on four-way junction DNA. Nucleic acids research 25: 3523-3531. (Pubitemid 27359231)
29. Musumeci D, Bucci EM, Roviello GN, Sapio R, Valente M, et al. (2011) DNA-based strategies for blocking HMGB1 cytokine activity: design, synthesis and preliminary in vitro/in vivo assays of DNA and DNA-like duplexes. Molecular bioSystems 7: 1742-1752.
30. Yanai H, Chiba S, Ban T, Nakaima Y, Onoe T, et al. (2011) Suppression of immune responses by nonimmunogenic oligodeoxynucleotides with high affinity for high-mobility group box proteins (HMGBs). Proceedings of the National Academy of Sciences of the United States of America 108: 11542-11547.
31. Chockalingam PS, Jurado LA, Jarrett HW (2001) DNA affinity chromatography. Molecular biotechnology 19: 189-199. (Pubitemid 32999911)
32. Yang H, Hreggvidsdottir HS, Palmblad K, Wang H, Ochani M, et al. (2010) A critical cysteine is required for HMGB1 binding to Toll-like receptor 4 and activation of macrophage cytokine release. Proceedings of the National Academy of Sciences of the United States of America 107: 11942-11947.
33. Li J, Wang H, Mason JM, Levine J, Yu M, et al. (2004) Recombinant HMGB1 with cytokine-stimulating activity. Journal of immunological methods 289: 211-223. (Pubitemid 38900918)
34. Qin S, Wang H, Yuan R, Li H, Ochani M, et al. (2006) Role of HMGB1 in apoptosis-mediated sepsis lethality. The Journal of experimental medicine 203: 1637-1642. (Pubitemid 44036267)
35. Macanovic M, Lachmann PJ (1997) Measurement of deoxyribonuclease I (DNase) in the serum and urine of systemic lupus erythematosus (SLE)-prone NZB/NZW mice by a new radial enzyme diffusion assay. Clinical and experimental immunology 108: 220-226. (Pubitemid 27223457)
36. Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(2Delta Delta C(T)) Method. Methods 25: 402-408. (Pubitemid 34164012)
37. Matta R, Barnard JA, Wancket LM, Yan J, Xue J, et al. (2012) Knockout of Mkp-1 exacerbates colitis in Il-10-deficient mice. American journal of physiology Gastrointestinal and liver physiology 302: G1322-1335.
38. Bianchi ME (1988) Interaction of a protein from rat liver nuclei with cruciform DNA. The EMBO journal 7: 843-849.
39. Wirtz S, Neurath MF (2005) Illuminating the role of type I IFNs in colitis. The Journal of clinical investigation 115: 586-588. (Pubitemid 40322229)
40. Madsen SM, Schlichting P, Davidsen B, Nielsen OH, Federspiel B, et al. (2001) An open-labeled, randomized study comparing systemic interferon-alpha-2A and prednisolone enemas in the treatment of left-sided ulcerative colitis. The American journal of gastroenterology 96: 1807-1815.
41. Nikolaus S, Rutgeerts P, Fedorak R, Steinhart AH, Wild GE, et al. (2003) Interferon beta-1a in ulcerative colitis: a placebo controlled, randomised, dose escalating study. Gut 52: 1286-1290. (Pubitemid 37026460)
42. Siiman O, Burshteyn A, Insausti ME (2001) Covalently Bound Antibody on Polystyrene Latex Beads: Formation, Stability, and Use in Analyses of White Blood Cell Populations. Journal of colloid and interface science 234: 44-58. (Pubitemid 32545798)
43. Andrassy M, Volz HC, Igwe JC, Funke B, Eichberger SN, et al. (2008) High-mobility group box-1 in ischemia-reperfusion injury of the heart. Circulation 117: 3216-3226.
44. Yang H, Tracey KJ (2010) Targeting HMGB1 in inflammation. Biochim Biophys Acta 1799: 149-156.
45. Hubbard WJ, Choudhry M, Schwacha MG, Kerby JD, Rue LW 3rd, et al. (2005) Cecal ligation and puncture. Shock 24 Suppl 1: 52-57.
46. Kuhn R, Lohler J, Rennick D, Rajewsky K, Muller W (1993) Interleukin-10-deficient mice develop chronic enterocolitis. Cell 75: 263-274. (Pubitemid 23320290)
47. Andersson U, Tracey KJ (2011) HMGB1 is a therapeutic target for sterile inflammation and infection. Annual review of immunology 29: 139-162.
48. Lotze MT, Tracey KJ (2005) High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal. Nature reviews Immunology 5: 331-342. (Pubitemid 40516158)
49. Ombrellino M, Wang H, Ajemian MS, Talhouk A, Scher LA, et al. (1999) Increased serum concentrations of high-mobility-group protein 1 in haemorrhagic shock. Lancet 354: 1446-1447. (Pubitemid 29494763)
50. Sunden-Cullberg J, Norrby-Teglund A, Rouhiainen A, Rauvala H, Herman G, et al. (2005) Persistent elevation of high mobility group box-1 protein (HMGB1) in patients with severe sepsis and septic shock. Critical care medicine 33: 564-573. (Pubitemid 40365558)
51. Palone F, Vitali R, Cucchiara S, Pierdomenico M, Negroni A, et al. (2014) Role of HMGB1 as a Suitable Biomarker of Subclinical Intestinal Inflammation and Mucosal Healing in Patients with Inflammatory Bowel Disease. Inflamm Bowel Dis 20(8): 1448-1457.
52. Luger K, Mader AW, Richmond RK, Sargent DF, Richmond TJ (1997) Crystal structure of the nucleosome core particle at 2.8 A resolution. Nature 389: 251-260. (Pubitemid 27406632)